Company / Cash & Equivalents
Tandem Diabetes Care Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$90.6M
FY2025
5-year range
$58.9M / $172.5M
FY2021-FY2025
Trend
+30.9%
vs FY2024
Sector context
#114 of 148
Health Care
What the data says
Tandem Diabetes Care's cash & equivalents of $91M is lower than 77% of companies in the Health Care sector (FY2025). Cash & Equivalents has fluctuated over the past 10 years, ranging from $14M in FY2017 to $173M in FY2022.
Based on SEC 10-K filings.
$91M in FY2025 with a 5-year CAGR of -0.9%.
Improved from $59M to $91M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -19.3%
- 5-Year CAGR
- -0.9%
- 10-Year CAGR
- -
Sector benchmark
Bottom 23% in Health CareTop 77% of 148This company $90.6M Sector average $1.2B
▼
-92.3% below sector average
Key checks
Key Insights
- 5-year CAGR of -0.9%, indicating a declining trend.
- In FY2025, cash & equivalents increased 30.9% year-over-year.
- Ranks #114 out of 148 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -0.32 (distress zone, below 1.8 threshold)
- Negative profit margin: -20.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $90.6M | +30.9% |
| FY2024 | $69.2M | +17.6% |
| FY2023 | $58.9M | -65.9% |
| FY2022 | $172.5M | +142.4% |
| FY2021 | $71.2M | -24.8% |
| FY2020 | $94.6M | +84.9% |
| FY2019 | $51.2M | +22.4% |
| FY2018 | $41.8M | +205.3% |
| FY2017 | $13.7M | -69.3% |
| FY2016 | $44.7M | +3.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026